Browse Studies — Arctuva

Phase 2

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)

The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-…

Primary Progressive Multiple SclerosisPrimary Progressive MSPrimary Progressive Multiple Sclerosis (PPMS)+6 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Sundance Biosciences, Inc.NCT07840326

Observational

Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis: A Randomized Waitlist Controlled Trial (DEW Study)

The goal of this clinical trial is to learn if an online wellness program can lower fatigue and improve mood and quality of life in people with progressive mul…

Primary Progressive Multiple Sclerosis (PPMS)Secondary Progressive Multiple Sclerosis (SPMS)

Estimated

~$10 – $750

Actual pay is set by the research site.

University of IowaNCT07831928

Phase 1

Multi-center, Phase 1b/2 Clinical Study of an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy (C-CAR168) for the Treatment of Progressive Multiple Sclerosis Refractory to Standard Therapy

This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell t…

Multiple SclerosisPrimary Progressive Multiple SclerosisSecondary Progress Multiple Sclerosis (SPMS)+6 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

AbelZeta Inc.NCT07825389